Concepedia

Kumudha Balakrishnan

KB

32

Publications

3.3K

Citations

27

H-Index

2005

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of Wisconsin–Milwaukee

The University of Texas Health Science Center at Houston

Infinity Pharmaceuticals (United States)

BioCryst Pharmaceuticals (United States)

Kumudha Balakrishnan is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pharmacology, and cell biology.

Top concepts

Publications per year

2005–2020

32

Publications

32

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

Sabine Ponader, Shih-Shih Chen, Joseph J. Buggy et al. · Blood · 2011 · 632 citations · Full text

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

Antonina V. Kurtova, Kumudha Balakrishnan, Rong Chen et al. · Blood · 2009 · 315 citations · Full text

Hydrogen Peroxide Inducible DNA Cross-Linking Agents: Targeted Anticancer Prodrugs

Yunyan Kuang, Kumudha Balakrishnan, Varsha Gandhi et al. · Journal of the American Chemical Society · 2011 · 306 citations · Full text

, , +15

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406

Maite P. Quiroga, Kumudha Balakrishnan, Antonina V. Kurtova et al. · Blood · 2009 · 238 citations · Full text

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

Fabiola Cervantes-Gomez, Betty Lamothe, Jennifer A. Woyach et al. · Clinical Cancer Research · 2015 · 213 citations · Full text

Rows per page

1–5 of 32